Anrikefon
Phase 3Small molecule
Anrikefon is one of 20 small molecule programs targeting Postoperative Analgesia. It is currently in Phase 3.
3
Indications
4
Total Trials
4
Active Trials
19
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
24 competitors in Postoperative Analgesia
#DrugCompanyPhaseTrials
1Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Duragesic
CCephalon
Approved
Decadron
AAspen Global Incorporated
Approved
Nubain
AAultman Health Foundation
Approved
Celebrex
PPhiladelphia Eye Associates
Approved
EXPAREL
Pacira Pharmaceuticals, IncApproved
Intrathecal Morphine
Pacira Pharmaceuticals, IncPhase 3
Bupivacaine Only
Pacira Pharmaceuticals, IncPhase 3
Advil
KKenvue Brands
Phase 2
Anrikefon
ZZhujiang Hospital
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Postoperative Analgesia1 trial
Post Operative Pain1 trial
Pruritus Chronic1 trial
Gallbladder Stones1 trial
A Multicenter, Randomized, Parallel-Group Controlled Study Evaluating the Efficacy and Safety of Anrikefon in Postoperative Pain Management in Patients Undergoing Elective Laparoscopic Cholecystectomy Under General Anesthesia
Not yet recruiting·AAffiliated Hospital of Guangdong Medical University·Phase 2·NCT07741188·144 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Anrikefon. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- ZZhujiang Hospital